Skip to main content

MDRNA Inks Early-Stage Collaboration Related to miRNA Therapies

Premium

MDRNA said this week that it has signed a new early collaborative effort with an undisclosed company focused on microRNA-directed oncology therapies.

According to the company, the arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models." Additional terms of the deal were not disclosed.

The DiLA2 technology relates to synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.